Angioedema Clinical Trial
Official title:
Evaluation of the Efficacy of Kallikrein Inhibition by Lanadelumab for Patients With Bradykinin Angioedema: a Cohort Study
A multicenter observational study aiming to evaluate the efficacy of kallikrein inhibition by lanadelumab in patients with bradykinin- angioedema
The bradykinin-angioedema (AE-BK) is characterized by recurrent and unpredictable episodes of swelling; it can be disabling and disfiguring and the attacks affecting the larynx can be life-threatening. The clinical symptoms depend on accumulation of bradykinin (BK), a vasoactive peptide responsible for vasodilation and increase of vascular leakage. BK formation depends on activation of the kallikrein-kinin cascade leading to uncontrolled generation of plasma kallikrein and subsequent proteolysis of high molecular-weight kininogen (HK). Lanadelumab is a fully human monoclonal antibody inhibitor of plasma kallikrein, thereby preventing BK production; it represents an attractive therapeutic strategy for BK-AE prophylaxis. The aim of this study is to evaluate the kallikrein inhibition by assessing the levels of cleaved HK and the immunogenicity of the lanadelumab. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT00163839 -
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
|
N/A | |
| Recruiting |
NCT03845946 -
CLOUD-R HAE REGISTRY
|
||
| Completed |
NCT00876369 -
Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
|
||
| Completed |
NCT02833675 -
Determination of Specific Biomarkers of Angioneurotic Crisis
|
N/A | |
| Completed |
NCT06096077 -
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
|
||
| Completed |
NCT00125541 -
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
|
Phase 2/Phase 3 | |
| Completed |
NCT01371877 -
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
|
N/A | |
| Completed |
NCT04206605 -
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
|
Phase 3 | |
| Unknown status |
NCT01036659 -
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
|
Phase 2 | |
| Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
| Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
| Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
| Completed |
NCT03240991 -
Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
|
||
| Completed |
NCT01723072 -
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
|
Phase 3 | |
| Completed |
NCT00385372 -
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria
|
N/A | |
| Completed |
NCT00004694 -
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
|
N/A | |
| Not yet recruiting |
NCT06210698 -
Angioedema Biomarker Research Study
|
||
| Terminated |
NCT04128371 -
Mepolizumab in Episodic Angioedema With Eosinophilia
|
Phase 2 | |
| Completed |
NCT04444895 -
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
|
Phase 3 | |
| Completed |
NCT00125151 -
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
|
Phase 3 |